BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 17532288)

  • 1. Drug treatment of hyperprolactinemia.
    Chanson P; Borson-Chazot F; Chabre O; Estour B
    Ann Endocrinol (Paris); 2007 Jun; 68(2-3):113-7. PubMed ID: 17532288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperprolactinemia: pathophysiology and management.
    Verhelst J; Abs R
    Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
    Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
    Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactinoma and pregnancy: From the wish of conception to lactation.
    Maiter D
    Ann Endocrinol (Paris); 2016 Jun; 77(2):128-34. PubMed ID: 27130071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment issues in female hyperprolactinaemia.
    Crosignani PG
    Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):152-64. PubMed ID: 16288952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
    Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactinoma surgery.
    Jan M; Dufour H; Brue T; Jaquet P
    Ann Endocrinol (Paris); 2007 Jun; 68(2-3):118-9. PubMed ID: 17512893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the prolactin serum isoforms secreted by a pituitary adenoma associated with therapy.
    Morán C; Tena G; Fonseca ME; Ochoa R; Bermúdez JA; Zárate A
    Arch Med Res; 1994; 25(1):1-3. PubMed ID: 8019107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabergoline in the long-term therapy of hyperprolactinemic disorders.
    Ferrari C; Paracchi A; Mattei AM; de Vincentiis S; D'Alberton A; Crosignani P
    Acta Endocrinol (Copenh); 1992 Jun; 126(6):489-94. PubMed ID: 1642081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperprolactinemia after menopause: Diagnosis and management.
    Auriemma RS; Pirchio R; Pivonello R; Colao A
    Maturitas; 2021 Sep; 151():36-40. PubMed ID: 34446277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of hyperprolactinemic anovulation with the dopamin-agonist quinagolide].
    Koloszár S; Keresztúri A; Kovács L
    Orv Hetil; 2000 Jul; 141(29):1621-3. PubMed ID: 10962898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines for the diagnosis and treatment of hyperprolactinemia.
    Biller BM; Luciano A; Crosignani PG; Molitch M; Olive D; Rebar R; Sanfilippo J; Webster J; Zacur H
    J Reprod Med; 1999 Dec; 44(12 Suppl):1075-84. PubMed ID: 10649814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical course of hyperprolactinemia in children and adolescents: a review of 21 cases.
    Eren E; Yapıcı Ş; Çakır ED; Ceylan LA; Sağlam H; Tarım Ö
    J Clin Res Pediatr Endocrinol; 2011; 3(2):65-9. PubMed ID: 21750634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic evaluation of hyperprolactinemia.
    Biller BM
    J Reprod Med; 1999 Dec; 44(12 Suppl):1095-9. PubMed ID: 10649817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to manage intolerance to dopamine agonist in patients with prolactinoma.
    Stumpf MAM; Pinheiro FMM; Silva GO; Cescato VAS; Musolino NRC; Cunha-Neto MBC; Glezer A
    Pituitary; 2023 Apr; 26(2):187-196. PubMed ID: 37027090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperprolactinaemia and pituitary adenomas in adolescence.
    Dissaneevate P; Warne GL
    J Pediatr Endocrinol Metab; 1998; 11(4):531-41. PubMed ID: 9777574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.